July 30, 2016 6:00 AM ET


Company Overview of Infinity Pharmaceuticals, Inc.

Company Overview

Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; CONTEMPO that is in the Phase Ib/II study of IPI-145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma; BRAVURA, which is in Phase III study to evaluate the safety and efficacy of IPI-145 plu...

784 Memorial Drive

Cambridge, MA 02139

United States

222 Employees





Key Executives for Infinity Pharmaceuticals, Inc.

Chairman, Chief Executive Officer and President
Age: 56
Total Annual Compensation: $646.9K
Chief Financial Officer, Principal Accounting Officer, Chief Business Officer and Executive Vice President
Age: 50
Total Annual Compensation: $405.4K
President of Research & Development
Age: 61
Total Annual Compensation: $497.3K
Chief Commercial Officer and Executive Vice President
Age: 52
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2015.

Infinity Pharmaceuticals, Inc. Key Developments

Infinity Pharmaceuticals, Inc. Announces Executive Changes

On July 25, 2016, Christopher M. Lindblom, Infinity Pharmaceuticals, Inc.’s Vice President of Finance and Treasurer, agreed to transition his role as its principal accounting officer to Lawrence E. Bloch, M.D., J.D., its Executive Vice President, Chief Financial Officer and Chief Business Officer, effective July 25, 2016. Mr. Lindblom will continue in his role as Vice President of Finance and Treasurer. On July 25, 2016, Lawrence E. Bloch, M.D., J.D. was appointed to serve as principal accounting officer, effective immediately. Dr. Bloch, has served as Executive Vice President, Chief Financial Officer and Chief Business Officer since July 2012. Prior to joining the company, Dr. Bloch served as Chief Executive Officer of NeurAxon, Inc., from 2007 to 2011.

Infinity Pharmaceuticals, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-13-2016 10:15 AM

Infinity Pharmaceuticals, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-13-2016 10:15 AM. Venue: Le Parker Meridien, New York, New York, United States.

Infinity Pharma Lays Off Another 100 After AbbVie Ends Partnership

Infinity Pharmaceuticals is laying off another 100 employees just two weeks after laying off 46 researchers, this time after AbbVie opted out of a partnership on its main drug. The 100 new layoffs cut headcount by 58%, but added to the cuts announced June 14 when disappointing trial results of its blood cancer drug duvelisib was first announced.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Infinity Pharmaceuticals, Inc., please visit www.infi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.